Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies

被引:0
|
作者
ZS Pavletic
SS Joshi
SJ Pirruccello
SR Tarantolo
J Kollath
EC Reed
PJ Bierman
JM Vose
PI Warkentin
TG Gross
K Nasrati
JO Armitage
A Kessinger
MR Bishop
机构
[1] Section of Oncology and Hematology,Department of Internal Medicine
[2] University of Nebraska Medical Center,Department of Internal Medicine, Department of Cell Biology and Anatomy
[3] University of Nebraska Medical Center,Department of Internal Medicine, Department of Pathology and Microbiology
[4] University of Nebraska Medical Center,Department of Internal Medicine, Department of Preventive and Societal Medicine
[5] University of Nebraska Medical Center,undefined
来源
Bone Marrow Transplantation | 1998年 / 21卷
关键词
stem cell transplantation; allogeneic; lymphocytes;
D O I
暂无
中图分类号
学科分类号
摘要
Forty-one patients were studied at set times after allogeneic blood stem cell transplantation (alloBSCT) for recovery of lymphocyte numbers and function. Cells were mobilized with G-CSF from HLA-matched related donors and cryopreserved. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate; G-CSF was administered post-transplant. Median time to absolute lymphocyte count (ALC) ⩾500/μl was 17 days vs 41 and 49 days in historical alloBMT patients with G-CSF (n = 23) or no cytokine (n = 29) post-transplant, respectively (P < 0.0001). CD4/CD8+ ratio was 1.9 on day 28 after alloBSCT, then gradually declined to 0.8 at 1 year due to more rapid CD8+ cell recovery. Mean phytohemagglutinin-induced T cell responses were lower than normal on day +28 (P < 0.05), then tended to recover towards normal values. Natural-killer cytotoxicity remained low from day +28 to 1 year post-alloBSCT, but considerable lymphokine-activated killer cytotoxicity was induced from cells already obtained on day +28. Faster lymphocyte recovery correlated with better survival in alloBSCT patients (median follow-up 287 days, P = 0.002), ALC recovery was not affected by acute GVHD, CMV infections or doses of infused cells. ALC recovery did not correlate with survival in either historical alloBMT group. These data suggest that after alloBSCT lymphocyte reconstitution is faster than after alloBMT, and that quicker lymphocyte recovery predicts better survival in the alloBSCT setting.
引用
收藏
页码:33 / 41
页数:8
相关论文
共 50 条
  • [21] Allogeneic blood stem cell transplantation for hematologic malignancies: A safe effective alternative compared to allogeneic bone marrow transplantation.
    Mangan, KF
    Klumpp, TR
    BLOOD, 1998, 92 (10) : 353B - 353B
  • [22] Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: A retrospective comparison with marrow transplantation
    Bensinger, WI
    Clift, R
    Martin, P
    Appelbaum, FR
    Demirer, T
    Gooley, T
    Lilleby, K
    Rowley, S
    Sanders, J
    Storb, R
    Buckner, CD
    BLOOD, 1996, 88 (07) : 2794 - 2800
  • [23] Clinical options after failure of allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies
    Petrovic, Aleksandra
    Hale, Gregory
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2011, 7 (04) : 515 - 527
  • [24] Pulmonary Dysfunction in Survivors of Childhood Hematologic Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation
    Inaba, Hiroto
    Yang, Jie
    Pan, Jianmin
    Stokes, Dennis C.
    Krasin, Matthew J.
    Srinivasan, Ashok
    Hartford, Christine M.
    Pui, Ching-Hon
    Leung, Wing
    CANCER, 2010, 116 (08) : 2020 - 2030
  • [25] Immunologic reconstitution after allogeneic blood stem cell transplantation: Faster lymphocyte recovery correlates with better survival.
    Pavletic, ZS
    Bishop, MR
    Joshi, SS
    Tarantolo, SR
    Pirruccello, SJ
    Reed, EC
    Bierman, PJ
    Vose, JM
    Gross, TG
    Kollath, J
    Nasrati, K
    Armitage, JO
    Kessinger, A
    BLOOD, 1996, 88 (10) : 1678 - 1678
  • [26] Long-Term T Cell Immune Reconstitution in Patients Surviving 10 or More Years after Allogeneic Stem Cell Transplantation for Hematologic Malignancies
    Le, Quan
    Melenhorst, J. Joseph
    Savani, Bipin N.
    Hill, Brenna
    Memon, Sarfraz
    Shenoy, Aarthi
    Hensel, Nancy F.
    Koklanaris, Elefteria K.
    Keyvanfar, Keyvan
    Hakim, Fran
    Douek, Daniel
    Barrett, A. John
    BLOOD, 2008, 112 (11) : 428 - 429
  • [27] Extramedullary Relapse of Myeloid Malignancies after Allogeneic Blood Stem Cell Transplantation
    Schuler, Esther
    Boughoufala, Sarah
    Rautenberg, Christina
    Nachtkamp, Kathrin
    Dienst, Ariane
    Fenk, Roland
    Kondakci, Mustafa
    Germing, Ulrich
    Rudelius, Martina
    Schroeder, Thomas
    Haas, Rainer
    Kobbe, Guido
    BONE MARROW TRANSPLANTATION, 2018, 53 : 629 - 629
  • [28] AUTOLOGOUS BLOOD STEM-CELL TRANSPLANTATION IN HEMATOLOGIC MALIGNANCIES
    MAJOLINO, I
    SCIME, R
    INDOVINA, A
    HAEMATOLOGICA, 1990, 75 (06) : 555 - 566
  • [29] Lymphocyte subset reconstitution after allogeneic haematopoietic stem cell transplantation from unrelated donors
    Vavilov, V
    Zabelina, T
    Kroeger, N
    Fehse, B
    Fehse, N
    Pugachov, A
    Zander, A
    Afanasyev, B
    BONE MARROW TRANSPLANTATION, 2004, 33 : S173 - S173
  • [30] Allogeneic blood stem cell transplantation in advanced hematologic cancers
    Przepiorka, D
    Anderlini, P
    Ippoliti, C
    Khouri, I
    Fietz, T
    Thall, P
    Mehra, R
    Giralt, S
    Gajewski, J
    Deisseroth, AB
    Cleary, K
    Champlin, R
    vanBesien, K
    Andersson, B
    Korbling, M
    BONE MARROW TRANSPLANTATION, 1997, 19 (05) : 455 - 460